GlassScriptPhysician profile
Mark T Day
NPI 1225492796
$1,295.37
in general payments reported to CMS, 2019-2025
22 companies · $418 in 2025
The $418 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $37.89 · 2022: $252 · 2023: $262 · 2024: $326 · 2025: $418.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,006.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,005.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $159.38 | 2023-2025 | Lokelma, Farxiga |
| Boston Scientific Corporation | $157.63 | 2023-2024 | Watchman Access System, Versacross Access Solution |
| Abbvie INC. | $134.50 | 2019-2022 | |
| Abbott Laboratories | $124.37 | 2022-2023 | Mitraclip |
| Alnylam Pharmaceuticals INC. | $118.80 | 2025 | Amvuttra |
| Abiomed | $61.79 | 2023-2025 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $57.90 | 2024-2025 | Lifevest |
| Kiniksa Pharmaceuticals International, Plc | $57.31 | 2024 | Arcalyst |
| Novartis Pharmaceuticals Corporation | $51.87 | 2025 | |
| Heartflow, INC. | $51.03 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $45.93 | 2023-2024 | Eliquis, Camzyos |
| Cvrx, INC. | $43.33 | 2024 | Barostim Neo System |
| Shockwave Medical, INC | $35.93 | 2025 | |
| United Therapeutics Corporation | $28.53 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.31 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $26.87 | 2019 | |
| Inari Medical, INC. | $21.28 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Edwards Lifesciences Corporation | $20.84 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Pfizer INC. | $20.59 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.23 | 2025 | Jardiance |
| Novo Nordisk INC | $15.95 | 2024 | Wegovy |
| Terumo Medical Corporation | $14.00 | 2023 | Azur Cx Detachable |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Day listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.